CTOs on the Move

Cleave Biosciences

www.cleavebio.com

 
Cleave Biosciences is a biopharmaceutical company pioneering the development of novel protein homeostasis inhibitors for the treatment of cancer.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.cleavebio.com
  • 866 Malcolm Suite 100
    Burlingame, CA USA 94010
  • Phone: 650.443.3000

Executives

Name Title Contact Details

Funding

Cleave Biosciences raised $37M on 08/08/2016

Similar Companies

PharmaTech

PharmaTech is a Fort Lauderdale, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

DiaKine Therapeutics

DiaKine Therapeutics is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Interleukin Genetics

Interleukin Genetics Incorporated is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Juventas Therapeutics

Juventas Therapeutics is a private clinical-stage company developing novel therapies for ischemic cardiovascular disease. The company`s lead product` JVS-100` is a non-viral plasmid that encodes for stromal cell-derived factor-1 (SDF-1). SDF-1 has been shown to significantly increase end-organ function following tissue injury by promoting cell survival` recruiting endogenous stem cells to the damaged region` and promoting new blood vessel growth. The SDF-1 repair pathway is well conserved throughout end-organ systems providing the opportunity to impact a broad range of diseases. Target cardiovascular clinical indications address large markets with high unmet medical need and significant market potential. Juventas is currently enrolling multiple clinical trials to test therapy efficacy in heart failure and critical limb ischemia patients.

BioTheryX

BioTheryX is a clinical-stage biopharmaceutical company focused on restoring protein homeostasis through protein modulation, including protein degradation as well as multi-kinase inhibition, to develop treatments that extend and improve the quality-of-life of patients with life-threatening diseases.